Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness

O. M. HESS, J. GRIMM AND H. P. KRAYENBUEHL

Department of Internal Medicine, Medical Policlinic, Cardiology, University Hospital, Zurich, Switzerland

KEY WORDS: Myocardial stiffness, hypertrophic cardiomyopathy, propranolol, verapamil, left ventricular relaxation.

In patients with hypertrophic cardiomyopathy (HCM), impaired left ventricular (LV) relaxation and diastolic filling have been reported. Therefore, we determined LV diastolic stiffness in nine patients with HCM before and 10 to 15 min after 0.15 mg/kg propranolol i.v. (group 1) and in six patients with HCM before and 10 to 15 min after 0.1 mg/kg verapamil i.v. (group 2). Simultaneous LV cineangiography and high-fidelity pressure measurements were performed in group 1 and simultaneous M-mode echocardiography and high-fidelity pressure measurements in group 2. Passive LV chamber stiffness was determined in group 1 from the diastolic pressure-volume data using an exponential three-parameter model: \(P = a_\varepsilon P + C\), where \(P = \) pressure, \(a = \) intercept, \(\varepsilon = \) constant of chamber stiffness, \(V = \) volume and \(C = \) baseline pressure. Passive LV myocardial stiffness was estimated in group 2 from the diastolic stress-strain data using a viscoelastic model: \(\sigma = a'(\varepsilon ) + \eta\varepsilon\), where \(\sigma = \) meridional wall stress, \(a = \) intercept, \(\beta = \) constant of myocardial stiffness, \(\varepsilon = \) midwall strain, \(\eta = \) constant of myocardial viscosity and \(\varepsilon = \) strain rate. LV relaxation was assessed from the time constant of LV pressure decay (\(T\)) by plotting LV pressure versus negative dP/dt. LV diastolic filling was evaluated from peak and mean LV filling rate in group 1 and from peak and mean midwall lengthening rate in group 2.

LV chamber and myocardial stiffness, respectively, remained unchanged before and after administration of propranolol (\(\beta = 0.054\) and 0.047) and verapamil (\(\beta' = 14.8\) and 12.6); however, the time constant of LV pressure decay \(T\) increased significantly in group 1 from 45 to 66 ms (\(P < 0.05\)) and decreased significantly in group 2 from 53 to 43 ms (\(P < 0.05\)). Parallel to the changes in LV isovolumic relaxation, mean LV diastolic filling rate decreased significantly in group 1 from 257 to 196 ml m\(^{-2}\) s\(^{-1}\) (\(P < 0.025\)) and mean LV midwall lengthening rate increased significantly in group 2 from 2.37 to 3.31 cm/sec (\(P < 0.05\)).

It is concluded that LV diastolic stiffness remains unchanged in patients with HCM after propranolol and verapamil. LV relaxation and mean diastolic filling, however, are impaired in patients with HCM following propranolol but are improved after verapamil. Thus, the beneficial effect of verapamil on diastolic mechanics is related to improved relaxation and diastolic filling rather than to changes in LV diastolic stiffness.

Introduction

Abnormal left ventricular diastolic function and impaired left ventricular filling dynamics\(^1\) have been reported in patients with hypertrophic cardiomyopathy. The increased resistance to ventricular filling (diastolic compliance failure) is probably responsible for clinical symptoms such as dyspnea and lung congestion, and is considered to be the major problem in patients with hypertrophic cardiomyopathy, irrespective of the presence or absence of a systolic outflow gradient. A favourable effect of \(\beta\) blocking agents on the systolic outflow tract gradient is well established, whereas it remains controversial whether the passive diastolic chamber stiffness is altered by the administration of \(\beta\) blocking agents\(^5,6\). Kaltenbach and coworkers\(^7\) reported a salutary response to verapamil in patients with hypertrophic cardiomyopathy, and recently Lorell and coworkers\(^8\) showed a favourable effect of nifedipine on abnormal left ventricular relaxation and diastolic filling rates in patients with hypertrophic cardiomyopathy.

The purpose of the present study was, therefore, to evaluate the effects of propranolol and verapamil on...
left ventricular diastolic mechanics in 15 patients with hypertrophic cardiomyopathy, and to determine whether or not relaxation and passive diastolic chamber and myocardial stiffness can be influenced by the administration of these drugs.

**Patients and methods**

Fifteen patients with the typical clinical, haemodynamic, echocardiographic and angiographic findings of hypertrophic cardiomyopathy were included in the present study. All patients were in sinus rhythm and all medications were discontinued 24 to 48 h prior to catheterization.

Nine patients (group 1) were studied at rest and 10 to 15 min after intravenous administration of 0.15 mg/kg propranolol, and six patients (group 2) were studied 10 to 15 min after intravenous administration of 0.1 mg/kg verapamil. Three patients of group 1 had undergone previous septal myectomy, and two of them had left bundle branch block following surgery (QRS duration 0.14 s in both). In all other patients QRS duration did not exceed 0.11 s. The mean age was similar in both groups (43 and 47 years, respectively). The nine patients of group 1 have been published previously. Four patients of group 1 had no pressure gradient at rest but developed one after postextrasystolic potentiation or Valsalva manoeuvre; in group 2, three patients demonstrated only small systolic pressure gradients (<10 mmHg) at rest.

Standard haemodynamic measurements were performed in both groups at rest and 10 to 15 min after the administration of propranolol or verapamil. Left ventricular pressure was measured with a transseptally introduced Millar micromanometer; simultaneous aortic pressure was determined by a fluid-filled catheter. Biplane cineangiography was performed at 50 frames/s in the right (RAO) and left anterior oblique (LAO) projection with simultaneous recordings of left ventricular high-fidelity pressure, its first derivative (dP/dt) and a peripheral lead of the standard electrocardiogram. In group 1 patients a second biplane cineangiogram was carried out 10 to 15 min following intravenous administration of propranolol (Fig. 1).

Simultaneous M-mode echocardiography and high-fidelity pressure measurements (Fig. 2) were performed in group 2 patients at rest and 10 to 15 min after intravenous administration of 0.1 mg/kg verapamil. Left ventricular high-fidelity pressure, conventional aortic pressure, dP/dt, the phonocardiogram and a peripheral lead of the standard electrocardiogram were recorded on an oscillograph (Electronics for Medicine VR-12) at a paper speed of 100 mm/s.

**Data analysis**

Frame by frame analysis was performed for determination of left ventricular biplane volume in group 1 according to the area-length method. Matching of the individual cineframe with the left ventricular high-fidelity pressure was carried out by a numerical
Figure 2 Left ventricular simultaneous echo-pressure measurements in a patient with hypertrophic cardiomyopathy before (upper panel) and after (lower panel) intravenous administration of 8 mg verapamil. Note that there is a small systolic pressure gradient between the left ventricular (LVP) and the aortic pressure (AoP) tracing after verapamil. The heavy echo in the mid-portion of the left ventricular cavity stems from the Millar tip manometer. IVS, interventricular septum; PW, posterior wall; dP/dt, first derivative of LVP; ECG, electrocardiogram; PCG, phonocardiogram; D, diameter; P, pressure.

The code which appeared on both the cinefilm and the pressure tracing.*

The M-mode echoangiograms and high-fidelity pressure tracings (Fig. 2) in group 2 were digitized by a computer-assisted system, and instantaneous left ventricular internal and midwall diameter, meridional wall stress and midwall lengthening rate were calculated at time intervals of 5 to 10 ms.\textsuperscript{1}

For the assessment of left ventricular chamber stiffness, the pressure–volume data in group 1 were fitted to an exponential pressure–volume relationship using a three-parameter model:

\[
P = ae^{bV} + C,
\]

where \(P\) = pressure (mmHg), \(a\) = intercept (mmHg), \(b\) = constant of left ventricular chamber stiffness, \(V\) = volume (ml/m\(^2\)) and \(C\) = baseline pressure (mmHg). The mathematical analysis was performed by an iteration procedure\textsuperscript{10} using a non-linear curve-fitting program\textsuperscript{11} to determine the three constants \(a\), \(b\) and \(C\).

For the assessment of left ventricular myocardial stiffness the stress–strain data in group 2 were fitted to an exponential viscoelastic stress–strain model incorporating an elastic and a viscous term\textsuperscript{10}:

\[
s = a'(e^{b\xi} - 1) + \eta \xi,
\]

where \(s\) = meridional wall stress (g/cm\(^2\)),
\[ \alpha' = \text{intercept (g/cm}^2\text{)}, \quad \beta' = \text{constant of left ventricular myocardial stiffness,} \quad \varepsilon = \text{midwall strain,} \quad \eta = \text{constant of left ventricular myocardial viscosity (g s cm}^{-2}\text{)} \quad \text{and} \quad \dot{\varepsilon} = \text{strain rate (s}^{-1}\text{).} \]

Left ventricular midwall strain \((\varepsilon)\) was normalized to a reference midwall circumference \((I)\) at a common wall stress of 1 g/cm\(^2\) calculated from the viscoelastic stress–circumference relationship\(^{10}\). This midwall circumference at 1 g/cm\(^2\) \((I)\) was used for the determination of normalized midwall (natural) strain:

\[ \varepsilon_n = \ln(I/I_0). \]

The mathematical analysis for the evaluation of the myocardial stiffness constants was carried out by an iteration procedure\(^{10}\) using the non-linear curve-fitting program\(^{11}\).

For the assessment of left ventricular relaxation the time constant of left ventricular pressure decay \((T, \text{in milliseconds})\) was calculated from the linear regression between negative \(\frac{dP}{dt}\) and left ventricular pressure after peak negative \(\frac{dP}{dt}\) up to mitral valve opening:

\[ \frac{dP}{dt} = \frac{1}{T} (P - P_B), \]

where \(P = \text{left ventricular pressure (mmHg)}\) and \(P_B = \text{pressure intercept at} \frac{dP}{dt} = 0\)\(^{9,12}\).

For the assessment of left ventricular filling, peak filling rate was determined in group 1 from left ventricular cineangiograms. The mean filling rate was calculated from the stroke volume divided by the diastolic (mitral valve opening to end-diastole) filling time interval. Left ventricular peak and mean midwall lengthening rate were determined from the digitized M-mode echocardiograms\(^9\).

**Results**

**ECHOCARDIOGRAPHIC FINDINGS (TABLE 1)**

Septal wall thickness (>1·3 cm) and the ratio of septal to posterior wall thickness (>1·3) were increased in all patients. Left ventricular internal diameter and systolic shortening were similar in both groups. Systolic anterior motion (SAM) of the anterior mitral leaflet was present in eight of nine patients of group 1 and in five of six patients of group 2.

**STANDARD HAEMODYNAMIC MEASUREMENTS (TABLE 2)**

Heart rate decreased significantly from 85 to 69 beats/min following propranolol but remained unchanged in group 2 after verapamil (71 vs. 74 beats/min). Left ventricular end-diastolic and peak systolic pressure was unchanged after propranolol as well as after verapamil. The systolic pressure gradient decreased significantly from 22 to 12 mmHg following propranolol but remained unchanged after verapamil (28 vs. 30 mmHg). Left ventricular maximum \(\frac{dP}{dt}\) decreased slightly although not significantly in both groups after \(\beta\) blockade and verapamil. Left ventricular angiographic ejection fraction decreased slightly from 82 to 77% in group 1, whereas left ventricular end-diastolic volume index and systolic stroke volume remained unchanged after propranolol. Ejection fraction and end-diastolic volume in group 2 after administration of verapamil were comparable to the angiographic data in group 1 after propranolol. However, control data in group 2 were not available according to our protocol. The echocardiographic left ventricular end-diastolic diameter increased slightly from 3·92 to 4·04 cm after verapamil and systolic diameter shortening decreased significantly from 35 to 30%.

**DIASTOLIC FUNCTION PARAMETERS (TABLE 3)**

The diastolic pressure–volume data showed no significant change before and after propranolol (Fig. 3). The constant of left ventricular chamber stiffness \((\beta)\) and the intercept \((\alpha)\) decreased slightly although not significantly after \(\beta\) blockade. The baseline pressure \((C)\) increased slightly after propranolol.

The diastolic stress–strain data in group 2 showed no significant change in diastolic myocardial function after administration of verapamil (Fig. 4). The constant of left ventricular myocardial stiffness \((\beta')\) and the intercept \((\alpha')\) remained unchanged following verapamil. The constant of myocardial viscosity \((\eta)\) and the reference midwall circumference \((I)\) increased slightly although not significantly after verapamil.

**RELAXATION AND FILLING PARAMETERS (TABLE 4)**

\(T\) increased significantly from 45 to 66 ms in group 1 but decreased significantly from 53 to 43 ms in group 2. The number of \(T\) values elapsed at the lowest diastolic pressure \((T_a, \text{in ms})\), decreased slightly after propranolol but increased slightly after verapamil. The lowest diastolic pressure \((P_a)\) and peak negative \(\frac{dP}{dt}\) remained unchanged after both propranolol and verapamil.

Left ventricular peak filling rate remained unchanged in group 1 following propranolol, whereas the mean filling rate significantly decreased. The peak midwall lengthening rate in group 2 increased,
**Table 1  Echocardiographic findings**

<table>
<thead>
<tr>
<th></th>
<th>HR</th>
<th>$D_{ed}$</th>
<th>Sh</th>
<th>IVS</th>
<th>PW</th>
<th>IVS/PW</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>78</td>
<td>4.5</td>
<td>41</td>
<td>1.9</td>
<td>1.1</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>(60–94)</td>
<td>(3.7–5.6)</td>
<td>(35–38)</td>
<td>(1.3–2.2)</td>
<td>(0.9–1.2)</td>
<td>(1.5–2.2)</td>
</tr>
<tr>
<td>Group 2</td>
<td>75</td>
<td>4.4</td>
<td>39</td>
<td>1.9</td>
<td>1.1</td>
<td>1.7</td>
</tr>
<tr>
<td></td>
<td>(50–94)</td>
<td>(3.6–5.6)</td>
<td>(32–47)</td>
<td>(1.4–2.2)</td>
<td>(1.0–1.2)</td>
<td>(1.3–2.3)</td>
</tr>
</tbody>
</table>

HR, heart rate (beats/min); $D_{ed}$, left ventricular end-diastolic internal chamber diameter (cm); Sh, systolic shortening of the internal diameter (%); IVS, septal wall thickness (cm); PW, posterior wall thickness (cm); IVS/PW, septal to posterior wall ratio.

All data given are mean values and ranges.

**Table 2  Standard haemodynamics**

<table>
<thead>
<tr>
<th></th>
<th>HR</th>
<th>LVEDP</th>
<th>LVSP</th>
<th>$\Delta P$</th>
<th>max $dP/dt$</th>
<th>EF</th>
<th>EDVI</th>
<th>SVI</th>
<th>$D_{ed}$</th>
<th>Sh</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>C1</td>
<td>85±7</td>
<td>21±3</td>
<td>144±10</td>
<td>22±10</td>
<td>1842±121</td>
<td>90±6</td>
<td>73±5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pr</td>
<td>69±5</td>
<td>24±3</td>
<td>137±10</td>
<td>12±7</td>
<td>1613±105</td>
<td>77±3</td>
<td>95±5</td>
<td>73±3</td>
<td></td>
</tr>
<tr>
<td>Group 2</td>
<td>C2</td>
<td>71±4</td>
<td>17±4</td>
<td>152±10</td>
<td>28±13</td>
<td>1597±129</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3.9±0.3</td>
</tr>
<tr>
<td></td>
<td>V</td>
<td>74±7</td>
<td>17±2</td>
<td>146±8</td>
<td>30±9</td>
<td>1511±118</td>
<td>94±8</td>
<td>69±7</td>
<td>4.0±0.2</td>
<td>30±4</td>
</tr>
</tbody>
</table>

C1, control run group 1; Pr, propranolol; C2, control run group 2; V, verapamil; HR, heart rate (beats/min); LVEDP, left ventricular end-diastolic pressure (mmHg); LVSP, left ventricular peak systolic pressure (mmHg); $\Delta P$, systolic pressure gradient (mmHg); max $dP/dt$, maximal rate of left ventricular pressure rise (mmHg/s); EF, systolic ejection fraction (%); EDVI, left ventricular volume index (ml/m²); SVI, stroke volume index (ml/m²); $D_{ed}$, left ventricular internal diameter at end-diastole (cm); Sh, systolic shortening of the internal diameter (%); * P<0.05.

All data are given as mean values ±1 S.E.M.

**Table 3  Diastolic function data**

(a) Pressure–volume relationship: Group 1

<table>
<thead>
<tr>
<th></th>
<th>$\alpha$</th>
<th>$\beta$</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_1$</td>
<td>5.8±2.9</td>
<td>0.054±0.01</td>
<td>0.8±2.1</td>
</tr>
<tr>
<td>Pr</td>
<td>4.7±3.3</td>
<td>0.047±0.01</td>
<td>4.4±2.8</td>
</tr>
</tbody>
</table>

(b) Stress–strain relationship: Group 2

<table>
<thead>
<tr>
<th></th>
<th>$\alpha'$</th>
<th>$\beta'$</th>
<th>$\eta$</th>
<th>$l_1$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_2$</td>
<td>4.0±1.8</td>
<td>14.8±4.4</td>
<td>0.9±1.4</td>
<td>13.8±1.7</td>
</tr>
<tr>
<td>V</td>
<td>5.5±3.9</td>
<td>12.6±4.0</td>
<td>2.8±0.9</td>
<td>14.1±1.5</td>
</tr>
</tbody>
</table>

$\alpha$, intercept (mmHg); $\beta$, constant of chamber stiffness; $C$, baseline pressure (mmHg); $\alpha'$, intercept (g/cm²); $\beta'$, constant of myocardial stiffness; $\eta$, constant of myocardial viscosity (g s cm⁻²); $l_1$, left ventricular reference midwall circumference at a common wall stress of 1 g/cm² (cm); $C_1$, control run group 1; Pr, propranolol; $C_2$, control run group 2; V, verapamil.

All data are given as mean values ±1 S.E.M.
however, from 3.7 to 5.5 cm/sec and mean midwall lengthening rate increased significantly from 2.4 to 4.3 cm/sec following administration of verapamil.

Discussion

Improved relaxation and diastolic filling have been reported in patients with hypertrophic cardiomyopathy following administration of nifedipine.(8) A beneficial effect of β blocking agents on systolic outflow gradient has been well established, whereas the effect of β blocking agents on the passive diastolic properties remains a matter of controversy.(5,6) Therefore, the purpose of the present study was to examine the effect of propranolol and verapamil on left ventricular diastolic mechanics in order to determine whether or not left ventricular relaxation, diastolic filling and passive diastolic chamber and muscle properties are influenced by the administration of these drugs. The study group included not only patients with mild to moderate resting gradients but

![Figure 3](image1)

**Figure 3** Left ventricular pressure–volume relationship in a patient before (open circles) and after (closed circles) intravenous administration of propranolol. Note that the diastolic pressure–volume relationship remains unchanged after β blockade.

![Figure 4](image2)

**Figure 4** Left ventricular viscoelastic stress–strain relationship in a patient before (open circles) and after (closed circles) intravenous administration of verapamil. Note that the stress–strain relationship remains unchanged before and after administration of verapamil.
Table 4  Relaxation and filling data

(a) Group 1

<table>
<thead>
<tr>
<th></th>
<th>T</th>
<th>( T_{m} )</th>
<th>( P_L )</th>
<th>min ( dP/dt )</th>
<th>( I_p )</th>
<th>( I_m )</th>
</tr>
</thead>
<tbody>
<tr>
<td>( C_1 )</td>
<td>43±5</td>
<td>3.6±0.6</td>
<td>5.0±1.8</td>
<td>1417±80</td>
<td>607±125</td>
<td>256±32</td>
</tr>
<tr>
<td>( P_r )</td>
<td>66±11</td>
<td>3.3±0.5</td>
<td>5.2±1.6</td>
<td>1248±99</td>
<td>736±127</td>
<td>196±29</td>
</tr>
</tbody>
</table>

(b) Group 2

<table>
<thead>
<tr>
<th></th>
<th>T</th>
<th>( T_{m} )</th>
<th>( P_L )</th>
<th>min ( dP/dt )</th>
<th>( I_p )</th>
<th>( I_m )</th>
</tr>
</thead>
<tbody>
<tr>
<td>( C_2 )</td>
<td>53±7</td>
<td>4.7±0.7</td>
<td>5.0±0.9</td>
<td>1379±117</td>
<td>3.7±0.9</td>
<td>2.4±0.7</td>
</tr>
<tr>
<td>( V )</td>
<td>43±9</td>
<td>4.9±0.8</td>
<td>6.0±0.6</td>
<td>1379±98</td>
<td>5.5±1.1</td>
<td>4.3±0.8</td>
</tr>
</tbody>
</table>

\( T \), time constant of left ventricular pressure decay (ms); \( T_{m} \), \( P_L \), \( P \), \( I_p \), \( I_m \), \( LVP \), \( dP/dt \), \( dP/dt \) (mmHg/s); \( f_p \), left ventricular peak filling rate (ml m\(^{-2}\) s\(^{-1}\)); \( f_m \), left ventricular mean filling rate (ml m\(^{-2}\) s\(^{-1}\)); \( I_p \), left ventricular peak midwall lengthening rate (cm/s); \( I_m \), left ventricular mean midwall lengthening rate (cm/s); *\( P<0.05 \); **\( P<0.025 \); \( C_1 \), control run group 1; \( P_r \), propranolol; \( C_2 \), control run group 2; \( V \), verapamil.

All data are given as mean values±1 S.E.M.

also four patients with provocable systolic pressure gradients in group 1 and three patients with minimal resting outflow gradients (<10 mmHg) in group 2. Therefore, our results are valid for patients with no or moderate pressure gradients, and might not be extrapolated to patients with large outflow tract gradients who are operated on at our institution.

The data suggest that left ventricular relaxation is delayed in patients with hypertrophic cardiomyopathy following \( \beta \) blockade probably due to negative inotropic effect of propranolol and due to the change in heart rate\(^{12} \). In contrast, left ventricular relaxation is enhanced after administration of verapamil, probably due to a direct effect of the calcium channel blocker on the deactivation process in patients with hypertrophic cardiomyopathy. Since loading conditions were not significantly altered after verapamil, the changes in left ventricular relaxation cannot be explained by unloading of the left ventricle. Usually, 3 to 5 min

**Figure 5**  Left ventricular negative \( dP/dt \) vs. pressure plot in a patient with hypertrophic cardiomyopathy before and after propranolol (left hand panel) as well as before and after verapamil (right hand panel). The control data are represented by the open symbols and the propranolol and the verapamil data by the closed symbols. Note that the time constant of left ventricular pressure decay (\( T \)) is increased from 53 to 76 ms after propranolol but is decreased from 57 to 43 ms after verapamil. LVP, left ventricular pressure; \(-dP/dt\), negative \( dP/dt \).
after infusion of verapamil, there was an increase in heart rate and a decrease in aortic pressure due to peripheral vasodilatation. However, our measurements were performed 10 to 15 min after infusion of verapamil, when heart rate and aortic pressure were back to control (Table 1). The mild negative inotropic effect of verapamil with a decrease in systolic shortening of the left ventricular internal diameter would tend to decrease the rate of relaxation rather than to increase it. Thus, verapamil is associated with an improvement in left ventricular relaxation, and, therefore, facilitates diastolic filling by lowering early diastolic filling pressures. Therefore, one would expect an improved diastolic filling rate after administration of verapamil but a decreased filling rate after propranolol. Our data confirm that diastolic filling is improved after verapamil but is impaired after propranolol with a decrease in mean diastolic filling rate. The analysis of diastolic chamber and muscle stiffness, however, showed no change in left ventricular diastolic passive properties after the administration verapamil or propranolol.

Thus, we can conclude that the beneficial effect of verapamil on diastolic mechanics is related to improved relaxation and diastolic filling rather than to changes in myocardial wall stiffness. In contrast, the beneficial effect of propranolol appears to be related to the reduction of systolic outflow gradient rather than to changes in diastolic filling or passive chamber stiffness. This might explain the lack of clinical improvement in some patients with hypertrophic cardiomyopathy treated with propranolol, especially those without outflow obstruction.

The work reported in this paper was supported by the Swiss National Science Foundation.

References


Kaltenbach In some respects your findings are in agreement with ours, but in others there is disagreement. This disagreement concerns systolic function after verapamil. If I am correct you have found a change towards improved diastolic function but no essential change in systolic function. We have found both improved diastolic function and reduced contractility. I assume the reason for this difference is the method of administering verapamil. If you compare a bolus of propranolol with a bolus of verapamil there are significant differences. I think a bolus injection of verapamil can only be evaluated if sympathetic activity is blocked or if the substance is given as a prolonged infusion or by oral administration. But if bolus administration of verapamil is evaluated, then the effect of the calcium blocker and the effect of increased sympathetic activity are superimposed.

Hess We did not want to blunt our results by administration of β-blocking agents before verapamil. It was actually not a bolus injection that
we used but rather an intravenous infusion for about 3 to 4 min. It was very interesting to see that after 2 or 3 min of verapamil administration, we had, first, an increase in most patients' pressure gradient. The measurements which we have presented here were made 10 to 15 min after administration of the drug, when the haemodynamic situation was almost back to the control level. You have seen that the heart rate was not significantly different before and after administration of verapamil.

Kaltenbach: It was an increase from 71 to 74 beats/min, this might not be a significant difference, but . . .

Hess: It was more, you know, when you look at the 5 min values after administration of verapamil; we had an increase from about 70 to 80 and then it came back 10 min after to the values which we had before. Although the pressure gradient was unchanged after 10 min, 5 min after administration we saw in most patients an increase in outflow gradient.

And now to your other question. We have seen in some patients a decrease in contractility. We have studied six patients with verapamil only and we have seen a slight decrease in \( \frac{dP}{dt} \) and also in the ejection fraction was also lower, 73% after verapamil as compared to 82% in group 1 at rest. I think we had a mild effect on systolic function.

Bertrand: I have two questions. Have you studied the effects of other calcium antagonists, especially nifedipine, in these particular patients? My second question is: Obviously, when you are injecting verapamil intravenously, you have direct myocardial effects and also peripheral effects. Have you studied the direct myocardial effect by injecting the drug directly into the left coronary artery, in order to separate the two effects of the drug?

Hess: To answer the second question first, we did not inject it directly because you know that you get asynchronous contractions when you inject directly in the coronary artery and you may not be sure what you are going to find; you probably see a decrease in everything because you have left ventricular asynchrony.

Now to your first question. In a non-invasive study, we evaluated the effects of nifedipine on relaxation. We have seen an increase in peak lengthening rate and found that filling was improved after the administration of nifedipine similar to our present study.

Schmiel: I would like to make some remarks and put some questions concerning the method you used. First, there exists one paper by Rutishauser from the late 1960s in which he demonstrated that the pressure fall during the relaxation period, during the isovolumic relaxation period, was not constant. That means, the ratio of \( \frac{dP}{dT} \) divided by the instantaneous pressure does not remain constant and that means the description by a function as Weiss used it is not adequate. You must use a modified exponential function to do this. The second thing is, how did you determine your strain from the dimensional data? I think it is practically impossible to determine the resting length of the heart muscle. The third point is a remark concerning these parameters that you determined by a non-linear fitting. Our experience is that if you analyse two or three consecutive heart beats, the parameters are significantly different from what you achieve by this analysis.

Hess: We are well aware that the downslope might not be linear for the \( \frac{dP}{dt} \) vs. \( P \) regression. As Dr. Murgo pointed out, there might be a biphasic slope and there might be some other problem with this kind of analysis. However, you all know that after propranolol with a decrease in contractility there must be a decrease in the rate of relaxation. With verapamil you can see an increase in relaxation rate, as it was shown in the paper of Lorell and coworkers. The way in which we do our analysis might be wrong. Maybe in patients with hypertrophic cardiomyopathy and asymmetric hypertrophy we should better use a regional relaxation parameter. I do not know an answer, but this is probably the best way as we did it.

Now to the second point, we had a publication some years ago where we showed that you can't get zero pressure in patients because you can't do caval occlusion and bring the lowest pressure down to zero. Thus, we use an extrapolation procedure; here we do first a fit to the pressure–circumferential wall length relation and determine the circumferential length at the calculated stress of 1 g/cm\(^2\) or the calculated volume of 1 mmHg. This length is used for normalization. This is an assumption, probably the best one, to get normalized data in patients.

Now to the third point, to the analysis of consecutive beats. Our data showed that there was no change before and after propranolol and before and after verapamil. This shows that the model used was
probably okay, because we could not see any difference between the patients. If you see a difference from beat to beat, then you must have used the wrong model, I should say.

Schmied You demonstrated only the plots, but not the parameter of the curves, and the plots seem to be identical, but I believe that the parameters of the curves are significantly different.

Hess No, they were exactly the same; the single parameters were on the top of the figure. You could see that the stiffness data were the same.

Frank We have found that the time to maximum improvement clinically is often as much as 2 years from the beginning of the administration of propranolol. Do you have any data with repeated invasive studies, assuming that the method of measurement is at least satisfactory from the point of view using the patient as his own control?

Hess No. Professor Rothlin will show some data of a clinical follow-up study of patients with propranolol and verapamil. These patients showed a lower mortality rate than untreated patients. We did not repeat our measurements, otherwise you would have to recatheterize the patients. I am not sure if you would find different results.